Regeneron Pharmaceuticals Inc. KINGDOM,
He said Tuesday afternoon that the U.S. government has agreed to buy an additional 1.25 million doses of the company’s COVID-19 antibody cocktail. This would bring the US supply of the cocktail, consisting of casirivimab and imdevimab antibodies, to more than 1.5 million doses. Under the new agreement, the government will buy all finished doses of the cocktail delivered on June 30th. Regeneron already supplies doses to treat approximately 300,000 people, and President Donald Trump received treatment when he fell ill with COVID-19 last year. “COVID-19 continues to darken hundreds of thousands of Americans every day and the people of Regeneron are committed to helping,” Executive President Leonard S. Schleifer said in a statement. “We are pleased to work with the United States government to supply our antibody cocktail as an important weapon in this fight.” Patients who received the cocktail in clinical trials “experienced significant reductions in virus levels and required fewer medical visits for COVID-19, suggesting that therapy may help reduce the current burden on hospitals and systems. sanitary ware, ”the company said. The cocktail continues to be evaluated in clinical trials for the treatment of patients with COVID-19 in and out of hospitals, including a trial for the prevention of COVID-19 in contacts of infected people in homes, the company said. Regeneron shares rose nearly 5% in the extended session after the end of the regular trading day by 0.6%.